Cell and gene therapy

Dementia
#AAV #Cell and gene therapy #Cell and Gene Therapy Catapult #Dementia

New partnership looks to gene therapy for dementia  

The Cell and Gene Therapy Catapult (CGT Catapult) has partnered with the UK Dementia Research Institute (UK DRI) to help advance the development of adeno-associated virus (AAV) based gene therapies for dementia.  Through the collaboration, the CGT Catapult will work with UK academic centres and the UK… Read More

#News

Cell and gene therapy
#Biopharma #Cell and gene therapy #CRISPR

Selecting the best gene delivery method

Mirus Bio outlines when to use transfection reagents, viral transduction or electroporation. No single delivery method is ideal for all situations, but researchers may routinely employ a suboptimal approach for the sake of familiarity or to avoid any start-up costs associated with new methods. The uses of… Read More

#News

#Cell and gene therapy #Clinical development

Cell & gene therapy eBook: Insight into the latest research 

This 28-page DDW eBook, sponsored by Bio IVT, contains exclusive insight from industry experts on: Cell & gene therapies: the challenges and trends Battling the bottleneck: leveraging education to close the advanced therapy talent gap Cell and gene therapies: Opportunities for innovation Informing strategic decision-making in early clinical development… Read More

#News

Human brain
#Biopharma #Cell and gene therapy #EMA #Rare disease

Gene therapy for rare brain disease gets nod from EMA

A gene therapy targeting a rare brain disorder has received a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). PTC Therapeutics’ one-time gene replacement therapy Upstaza was given a positive opinion for the treatment for aromatic L-amino acid decarboxylase (AADC)… Read More

#News

#Biopharma #Cell and gene therapy #Manufacturing #Project Farma

Cell and gene therapies: Opportunities for innovation

By Dr. Deborah Phippard, Chief Scientific Officer of Precision for Medicine and Anshul Mangal, President & General Counsel, Project Farma. In recent years the advanced therapy industry has been the most significant disruptor in medicine. Cell and gene therapies are transforming the way diseases are treated but are also aiming to cure entirely new… Read More

#Business & Investment #Exclusive Content

#Cell and gene therapy #Immunology #SLAS Europe

The spring issue of Drug Discovery World magazine is out now 

Featuring Specialty Spotlight on Immunology, the magazine is available to download and read for free on the DDW App.    Key features of the spring issue include:  Can age-related disease be a thing of the past? Cell & Gene Therapies: Opportunities… Read More

#News

DNA vector
#Cell and gene therapy #Cell and Gene Therapy Catapult

Report sets out strategy for UK cell and gene therapy sector  

The Cell and Gene Therapy Catapult (CGT Catapult) has published recommendations on how the UK can continue to maintain its global advantage in the adoption of Advanced Therapy Medicinal Products (ATMPs).    The organisation’s ‘National Cell and Gene Therapy Vision for the UK’ outlines… Read More

#News

#Cell and gene therapy #Regulatory

ISCT to tackle regulatory and ethical issues 

The International Society for Cell & Gene Therapy (ISCT) has established a task force to address practical, ethical, and regulatory issues that arise from the use, and potential misuse, of expanded access within the cell and gene therapy (CGT) sector.   Context  Expanded access is… Read More

#News

#Biotechnology #Cell and gene therapy #Collaboration

Collaboration leads to new centre for cell therapy manufacturing 

Orgenesis, a global biotech company working with cell and gene therapies, and The Johns Hopkins University in the US, have collaborated to construct a cell and gene therapy processing facility for point of care treatment of patients at Johns Hopkins which is planned to start in the second quarter of… Read More

#News

#Cell and gene therapy #Funding

Ori Biotech raises over $100 million to launch CGT platform 

Ori Biotech, a producer of cell and gene therapy (CGT) manufacturing technology, has secured over $100 million in an oversubscribed Series B funding round and will use the funds to further expand key personnel across all functions, in order to rapidly transition through pre-commercialisation to the launch of its CGT manufacturing platform. … Read More

#News

#Cell and gene therapy #Cell and Gene Therapy Catapult #Life sciences

New data shows promising cell and gene therapy industry across the UK  

The Cell and Gene Therapy Catapult (CGT Catapult) has published new data in their 2021 Cell and Gene Therapy GMP manufacturing report and 2021 UK cell and gene therapy skills demand report. These reports highlight the continued growth across the UK’s Advanced Therapy Medicinal Product (ATMP) manufacturing capacity and… Read More

#News #Trending News

#Cell and gene therapy #Cell and Gene Therapy Catapult #Collaboration #Drug discovery

CGT Catapult’s creating opportunities in UK cell and gene therapy 

The Cell and Gene Therapy (CGT) Catapult has today published its Annual Review 2021, highlighting its key initiatives and impact in creating opportunities and investment in the UK cell and gene therapy industry.  2021 has reportedly emphasised the strength of the UK cell and gene therapy industry which experienced… Read More

#News

#Assays #Biotechnology #Cell and gene therapy #Cell therapy #iPSC

Ncardia secures $60+ million for its iPSC Offerings 

Ncardia, developer of stem cell-based solutions for drug discovery and cell therapy, has secured more than $60 million in capital through a strategic partnership with Kiniciti, a US-based investment platform.  Ncardia’s capabilities include bio-reactor-based scalable manufacturing of iPSC derived cells, assay development, disease modeling, and cell-based screening. … Read More

#News

#Cell and gene therapy #Cell and Gene Therapy Catapult #Drug delivery

Collaboration creates novel approach to the advanced therapy industry 

The Cell and Gene Therapy Catapult (CGT Catapult) and Deep Science Ventures have partnered to address barriers in the ATMP industry, create new companies and deliver better patient outcomes.  Recent advances in cell and gene therapies promise potential cures to devastating diseases. However, major hurdles still need to be… Read More

#News

#Cell and gene therapy #Cell therapy #Drug discovery #Funding

bit.bio receives $103 million for human cell production  

Human cell coding company bit.bio has closed a Series B financing of $103 million to accelerate the clinical development of the company’s cell coding technology opti-oxTM, a breakthrough gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently at scale through direct reprogramming of stem cells. … Read More

#News